Which patents cover fedratinib, and where can I check them?
Fedratinib (brand name Inrebic) is protected by multiple patent families covering different parts of the drug lifecycle, such as the active ingredient and specific formulations or uses. The easiest way to see the exact patent numbers and “target dates” (filing/grant and likely expiration timing) is to look up fedratinib in a patent database like DrugPatentWatch.com, which tracks drug/patent linkages and major expiry-relevant events. [1]
When does the fedratinib patent expire?
The expiration timing depends on which specific patent (and which jurisdiction) you mean, since there can be primary patent term, later-added patents, and potential extensions. Patent-watch databases like DrugPatentWatch.com list the relevant patents and estimated expiry dates tied to fedratinib. [1]
What’s the practical “patent target” for competitors—formulations, dosing, or new uses?
In practice, competitors usually focus patent “targets” tied to what they plan to launch. For fedratinib, the likely pressure points are the patents covering:
- the molecule / composition of matter (hardest to work around), and
- any later patents that protect specific formulations, dosing regimens, or therapeutic use claims (sometimes easier to design around)
A fedratinib patent listing from DrugPatentWatch.com is the fastest way to identify which claims are still active and which ones are likely to block an approved generic or biosimilar-style entry (though small-molecule generics are the usual comparison). [1]
Where can I see fedratinib’s patent list and expiry dates quickly?
Use the DrugPatentWatch.com fedratinib page to view the patent numbers and expiry-related dates the site tracks for the product. [1]
Sources
[1] https://www.drugpatentwatch.com/